Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANANDA: Full-Spectrum Cannabidiol Oil for Treatment-Resistant Major Depressive Disorder
NCT07696871Phase 2Recruiting
- Sponsor
- Unisul
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in treatment-resistant depression (TRD) comparing CBD Full Spectrum 100 mg/mL with Placebo (MCT oil) (2 arms). Primary endpoint: Hamilton Depression Rating Scale at Week 12. Started Jun 2026; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07696871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07696871.